For help on how to get the results you want, see our search tips.
654 results
Medicine
Paediatric investigation plans Remove Paediatric investigation plans filter
Summaries of opinion Remove Summaries of opinion filter
Categories
Human Remove Human filter
PIP decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) Remove RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) Remove P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Relamorelin (updated)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-002323-PIP02-19, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Age-appropriate oral dosage form, Solution for injection
Decision date: 09/09/2020, Last updated: 12/01/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): vaborbactam (updated)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-001740-PIP01-14, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for solution for infusion
Decision date: 22/10/2015, Last updated: 11/01/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231) (updated)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-002378-PIP01-18, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion, Age-appropriate dosage form for parenteral use
Decision date: 22/03/2019, Last updated: 09/01/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, baricitinib (updated)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-001220-PIP05-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Age-appropriate oral formulation
Decision date: 18/03/2020, Last updated: 09/01/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, benralizumab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001214-PIP05-19, Route(s) of administration: Subcutaneous use, Intravenous use, Pharmaceutical form(s): Solution for injection, Solution for injection/infusion, Age-appropriate dosage form for parenteral use
Decision date: 08/09/2021, Last updated: 22/12/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Pradigastat
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001333-PIP02-13, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 07/05/2014, Last updated: 22/12/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ritonavir, atazanavir sulfate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-002588-PIP01-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 04/12/2019, Last updated: 06/12/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Cendakimab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-002640-PIP01-19, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 08/09/2021, Last updated: 02/12/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Voclosporin
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-002264-PIP01-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, soft
Decision date: 17/04/2019, Last updated: 02/12/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-001970-PIP02-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Oral suspension
Decision date: 07/12/2018, Last updated: 23/11/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Linear single strand of deoxyribonucleic acid (encoding human retinitis pigmentosa GTPase regulator [RPGR]) packaged in a recombinant adeno-associated virus protein capsid of serotype 5 (AAV5-hRKp.RPGR)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Ophthalmology
PIP number: EMEA-002827-PIP01-20, Route(s) of administration: Ophthalmic use, Pharmaceutical form(s): Solution for injection
Decision date: 17/03/2021, Last updated: 17/11/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Entyvio, vedolizumab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology; Immunology-Rheumatology-Transplantation
PIP number: EMEA-000645-PIP03-18, Route(s) of administration: Intravenous use, Subcutaneous use, Pharmaceutical form(s): Powder for concentrate for solution for infusion, Solution for injection
Decision date: 14/08/2019, Last updated: 09/11/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Sparsentan
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Uro-nephrology
PIP number: EMEA-001984-PIP03-20, Route(s) of administration: Oral use, Pharmaceutical form(s): Age-appropriate oral liquid dosage form, Tablet
Decision date: 27/01/2021, Last updated: 07/11/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): ketamine (hydrochloride), sufentanil citrate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pain
PIP number: EMEA-001739-PIP02-16, Route(s) of administration: Intranasal use, Pharmaceutical form(s): Nasal spray, solution
Decision date: 06/12/2019, Last updated: 27/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Giroctocogene fitelparvovec
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-002724-PIP01-19-M01, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for infusion
Decision date: 05/08/2021, Last updated: 14/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): cenobamate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: EMEA-002563-PIP02-19-M01, Route(s) of administration: Oral use, Parenteral use, Gastric use, Pharmaceutical form(s): Tablet, Film-coated tablet, Age-appropriate oral liquid dosage form, Age-appropriate dosage form for parenteral use
Decision date: 13/08/2021, Last updated: 14/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Lebrikizumab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Dermatology
PIP number: EMEA-002536-PIP01-18-M01, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 11/08/2021, Last updated: 14/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Phenobarbital
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: EMEA-002532-PIP01-18-M01, Route(s) of administration: Oral use, Gastric use, Pharmaceutical form(s): Oral suspension
Decision date: 13/08/2021, Last updated: 14/09/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001933-PIP01-16-M01, Route(s) of administration: Intraosseous use, Pharmaceutical form(s): Dispersion for injection
Decision date: 12/06/2020, Last updated: 01/07/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Isavuconazonium sulfate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-001301-PIP01-12, Route(s) of administration: Intravenous use, Oral use, Pharmaceutical form(s): Powder for solution for infusion, Capsule, hard
Decision date: 14/06/2013, Last updated: 29/06/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Humanized anti-CD19, Fc engineered, monoclonal antibody (XmAb5871)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-002414-PIP01-18, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 16/08/2019, Last updated: 16/06/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Expanded human autologous mesenchymal adult stem cells extracted from adipose tissue (CX-401)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-000635-PIP01-09, Route(s) of administration: Intralesional use, Pharmaceutical form(s): Suspension for injection
Decision date: 19/02/2010, Last updated: 14/06/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Recombinant human heparan-N-sulfatase
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: EMEA-001634-PIP01-14, Route(s) of administration: Intrathecal use, Pharmaceutical form(s): Solution for injection/infusion
Decision date: 30/01/2015, Last updated: 14/06/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): arimoclomol citrate
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: EMEA-001748-PIP03-19, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 28/01/2021, Last updated: 10/06/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Deleobuvir
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-001389-PIP01-12, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Oral solution
Decision date: 24/09/2013, Last updated: 09/06/2022, Compliance check: X